Orchestra BioMed Investor Relations Blog | April 2026
The second Breakthrough Device Designation awarded to AVIM Therapy underscores its potential in a defined high-risk population and supports an accelerated development pathway.
Yesterday, we shared exciting news that Orchestra BioMed has been awarded FDA Breakthrough Device Designation for our novel AVIM therapy. If you missed the announcement, here’s a quick overview of this significant clinical and regulatory milestone:
This week marks a major milestone for Orchestra BioMed that has potentially significant implications for the commercial potential of AVIM therapy that OBIO is pursuing with its strategic partner, Medtronic.
